After The Dust Has Settled, Key Sarepta Therapeutics Insiders Are Still Buying Shares And So Should InvestorsSeeking Alpha • 08/30/19
Sarepta May Have Lost The Battle For Latest FDA Approval Of DMD Drug, But It Will Win The WarSeeking Alpha • 08/22/19
Why Analysts Are Upbeat On Sarepta Despite A Notable FDA RejectionInvestors Business Daily • 08/22/19
Is the Options Market Predicting a Spike in Sarepta Therapeutics (SRPT) Stock?Zacks Investment Research • 08/22/19
Why Madison Square Garden, Hain Celestial Group, and Sarepta Therapeutics Slumped TodayThe Motley Fool • 08/20/19
Why The FDA Left Sarepta To 'Twist In The Wind' Over Its Newest DrugInvestors Business Daily • 08/20/19
Sarepta Dives After FDA Rejects Its Newest Muscular Dystrophy DrugInvestors Business Daily • 08/19/19
Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug ApplicationGlobeNewsWire • 08/19/19
Sarepta Therapeutics Inc (SRPT) President & CEO Douglas S Ingram Bought $2 million of SharesGuruFocus • 08/12/19